Most Aetna commercial plans are expected to continue covering Wegovy with prior authorization in 2026
Goliwas KF, Kashyap MP, Khan J, Sinha R, Weng Z, Oak ASW, et al
It plays a crucial role in various bodily processes, ensuring your body functions at its best
Licensed indications for the use of alternative GLP-1 RAs or the dual GIP/GLP-1 RA tirzepatide
Large-scale clinical trials have demonstrated that these modern metabolic treatments are highly effective, with semaglutide patients losing an average of 15% to 20% of their total body weight over 68 weeks
The effect of retatrutide on bone density is also yet to be seen, although other GLP-1s have been shown to cause a decrease in bone density proportional to weight loss